Amonafide

Amonafide
Clinical data
Trade names	Xanafide, Quinamed
ATC code	none;
Identifiers
	IUPAC name 5-amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione;
CAS Number	69408-81-7;
PubChem CID	50515;
ChemSpider	45804 ;
UNII	1Q8D39N37L;
KEGG	D10090 ;
ChEMBL	ChEMBL428676 ;
CompTox Dashboard (EPA)	DTXSID30219562 ;
Chemical and physical data
Formula	C16H17N3O3
Molar mass	299.330 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N;
	InChI InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3 ; Key:UPALIKSFLSVKIS-UHFFFAOYSA-N ;
	(verify)

Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.^[1]^[2]

It was being developed as an anti-cancer therapy by Antisoma.^[3]

As of 2008^[update], it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).^[4] In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.^{[citation needed]}

References

^ Allen SL, Lundberg AS (July 2011). "Amonafide: a potential role in treating acute myeloid leukemia". Expert Opinion on Investigational Drugs. 20 (7): 995–1003. doi:10.1517/13543784.2011.585756. PMID 21591994. S2CID 10999582.
^ Freeman CL, Swords R, Giles FJ (February 2012). "Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?". Expert Review of Hematology. 5 (1): 17–26. doi:10.1586/ehm.11.68. PMID 22272701. S2CID 26740617.
^ "Antisoma's Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial". Genetic Engineering & Biotechnology News. 29 March 2010. Archived from the original on 1 April 2010.
^ Clinical trial number NCT00715637 for "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study" at ClinicalTrials.gov

External links

Amonafide entry in the public domain NCI Dictionary of Cancer Terms
Clinical trials of amonafide at ClinicalTrials.gov

This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[Allen_2011-1] Allen SL, Lundberg AS (July 2011). "Amonafide: a potential role in treating acute myeloid leukemia". Expert Opinion on Investigational Drugs. 20 (7): 995–1003. doi:10.1517/13543784.2011.585756. PMID 21591994. S2CID 10999582.

[Freeman_2012-2] Freeman CL, Swords R, Giles FJ (February 2012). "Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?". Expert Review of Hematology. 5 (1): 17–26. doi:10.1586/ehm.11.68. PMID 22272701. S2CID 26740617.

[3] "Antisoma's Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial". Genetic Engineering & Biotechnology News. 29 March 2010. Archived from the original on 1 April 2010.

[4] Clinical trial number NCT00715637 for "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study" at ClinicalTrials.gov

[1]

[2]

[3]

[4]

See also

References

External links